Fresh Tracks Therapeutics Overview
Get informed when a big investor buys or sells
+ Follow1.34
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
Fresh Tracks Therapeutics (FRTX) currently reports a PEG ratio of 1.34. That is above the Healthcare sector average of -5.81. Use the charts on this page to explore Fresh Tracks Therapeutics's PEG ratio history and peer comparisons.
Fresh Tracks Therapeutics's PEG ratio of 1.34 is higher than the Healthcare sector average of -5.81. That is roughly 123.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The PEG ratio is a valuation multiple that relates Fresh Tracks Therapeutics's market price to a fundamental measure such as earnings, sales, or book value. At 1.34, FRTX can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current PEG ratio of 1.34, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -5.81. From there, open related valuation or income-statement pages for Fresh Tracks Therapeutics, and consider following FRTX for alerts when major investors trade the stock.
Fresh Tracks Therapeutics is classified in the Healthcare sector. On PEG ratio, it currently shows 1.34 versus a sector average near -5.81. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FRTX with unrelated industries.
